Your hives don't wait for the right time.

Chronic spontaneous urticaria — or chronic hives — means your body can break out in itchy welts without any clear trigger, and no warning before it happens. If you are already taking medicine for your hives but still having moderate or severe flares once or twice a month, you know how much that can disrupt a regular day. A work meeting, a Sunday morning, a cookout with family — hives don't check your calendar first. AllerVie Birmingham is hosting a Phase IIb research study (an early but important stage of testing in people) sponsored by ARS Pharmaceuticals, a company focused on fast-acting allergy medicines. The study is testing whether an investigational Epinephrine nasal spray may help ease hive flare symptoms. You would continue your current hive treatment and add the investigational spray when a flare starts. During the study, everyone receives all of the study treatments at different times, including a placebo — a look-alike spray without medicine (an "inactive" version). The study team will explain the schedule up front. Every participant receives close monitoring, scheduled visits, and a rescue option during flares throughout the study. There is no cost to you for study-related visits or the study medicine. You will also receive compensation for your time. The study team at AllerVie Birmingham includes allergists and immunologists who have worked in this community for years. You have the right to ask questions before you sign anything — and you can leave the study at any time, for any reason, without it affecting your regular care.